Evaluating the Benefits of Lenvatinib and Paclitaxel in Recurrent Gynecologic Cancers

Video
Conference|SGO Annual Meeting

Floor J. Backes, MD, discusses the results from a phase I trial investigating the combination of lenvatinib (Lenvima) and paclitaxel in patients with recurrent ovarian, fallopian tube, or peritoneal cancers.

Floor J. Backes, MD, associate professor at The Ohio State University Comprehensive Cancer Center, discussesthe results from a phase I trialinvestigating the combination of lenvatinib (Lenvima) and paclitaxel in patients with recurrent ovarian, fallopian tube, or peritoneal cancers.

The primary goal of the study was to find a recommended phase II dose. The trial established an 80 mg weekly of paclitaxel and a daily dose of lenvatinib at 60 mg, says Backes. The combination appeared safe and tolerable in these patients.

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
Related Content
AUA 2025: A Sneak Peek for Community Oncologists/Urologists

AUA 2025: A Sneak Peek for Community Oncologists/Urologists

Jordyn Sava
April 22nd 2025
Article

At AUA 2025, experts will present on novel bladder cancer therapies, advanced renal cell carcinoma comparisons, frailty in prostate cancer, and more.

Read More

Advancing the Treatment of Cervical and Endometrial Cancers

Advancing the Treatment of Cervical and Endometrial Cancers

June 15th 2021
Podcast

In season 2, episode 6 of Targeted Talks, Alexander B. Olawaiye, MD leads a discussion with Haider S. Mahdi, MD, about the modern approaches to treating cervical and endometrial cancers.

Listen

ADC Development in Ovarian Cancer: What’s Next for FRα and Beyond?

ADC Development in Ovarian Cancer: What’s Next for FRα and Beyond?

Chris Ryan
April 5th 2025
Article

Antibody-drug conjugates and their development remains a central theme in ongoing research within the realm of ovarian cancer.

Read More

Precision Medicine Guiding Ovarian Cancer Treatment

Precision Medicine Guiding Ovarian Cancer Treatment

July 15th 2020
Podcast

Sarah M. Temkin, MD leads discussion with Daphne B. Stewart, MD, around targeted therapies in ovarian cancer, whether offered in the academic or community setting.

Listen

Ocular Events With Mirvetuximab Show No Impact on QoL in Ovarian Cancer

Ocular Events With Mirvetuximab Show No Impact on QoL in Ovarian Cancer

Jordyn Sava
March 31st 2025
Article

Read More

FDA Backs Phase 3 Study of IMNN-001 in Advanced Ovarian Cancer

FDA Backs Phase 3 Study of IMNN-001 in Advanced Ovarian Cancer

Jordyn Sava
March 26th 2025
Article

A phase 3 trial will evaluate IMNN-001, the first immunotherapy to show an overall survival benefit in ovarian cancer.

Read More